OVERVIEW:

Ponsegromab  | PF-06946860 is a highly selective humanized monoclonal antibody that binds to circulating GDF-15, thereby inhibiting the interaction with its GFRAL receptor¹

RATIONALE FOR CANCER TARGET

• Cachexia (wasting syndrome) is prevalent among patients with multiple forms of cancer and can lead to weight loss, muscle wasting, reduced quality of life, functional impairment, and reduced survival¹
• Growth differentiation factor 15 (GDF-15) is a stress-induced cytokine that binds to the glial cell–derived neurotrophic factor family receptor alpha-like protein (GFRAL) in the hindbrain¹
• The GDF-15–GFRAL pathway has emerged as a main modulator of anorexia and body-weight regulation,² and elevated GDF-15 levels are associated with loss of weight and skeletal muscle mass along with reduced strength and survival in patients with cancer¹